08.18.25 -- As Billions Of Dollars Pour In, Do CDMO Valuations Matter?

Review the implementation of a holistic Contamination Control Strategy (CCS). Discover four key considerations for assessing component readiness: product, process, protection, and proof.

ADCs are targeting tumors directly to reduce side effects. Discover how they affect neighboring cells, which can enhance treatment efficacy and eliminate tumor cell populations.

Capacity constraints typically are accompanied by other challenges, including missed timelines, defect rates, and overall decreased satisfaction with pharma companies’ bioprocessing CDMOs.

Even after AI developers clean up hallucinations and other short-term issues, a large-scale workforce replacement faces a few intractable obstacles.

Explore how a CMO with innovative practices and a successful approach to tech transfer and manufacturing processes can help meet project timelines and mitigate risk on the path to market.

Learn about project-based insourcing solutions designed to give clients laboratory services support with flexible timeframes and eliminate worries about co-employment and other regulatory concerns.

Discover how this integrated, multi-parameter assay strategy can enhance the accuracy, sensitivity, and efficiency of your ADC potency evaluations.

Review the pros and cons of soluble and insoluble processes, experiences with isolating, solubilizing, and properly re-folding, and strategies and innovation to improve insoluble processes.

Examine how our innovative methods enable the precise identification of PEGylation sites, unlocking deeper insights into the structure, stability, and function of biotherapeutics.

Evaluating quality attributes of therapeutic proteins requires a strategic, regulation-compliant selection of analytical techniques that consider molecular characteristics and phase to ensure characterization.

Explore a solvent-free alternative for the production of amorphous solid dispersions (ASDs) that not only improves manufacturability but also reduces the carbon footprint of ASD manufacturing.

When choosing between protein expression formats such as transient versus stable pools, considerations include speed, cost, titre, and product quality.

Tailored drug release is evolving from formulation tactic to precision therapy strategy, optimizing timing, site, and rate of delivery for improved patient outcomes.

We are bringing additional services and capacity straight to the heart of Europe to support the rapid growth of advanced therapies in the region.

With extensive experience and capabilities, we foster a collaborative environment, developing and implementing innovative analytical methods to efficiently address the testing needs of our partners.

Meet the unique needs of your sterile injectable with global expertise, reliability, and flexibility to support your project every step of the way, from development to commercialization.

Enable an optimized process for mAb development and manufacturing, efficiency, and speed with exceptional quality, and high titers with lower-cost workflows for maximum ROI.